David Southwell

David Southwell

Former President, Chief Executive Officer and DirectoratTScan Therapeutics· In proxies 2022–2023

Pay in FY2023-40% from the year before · TScan Therapeutics stock +276.1% the same year

David Southwell was paid $1.3M in FY2023 (Dec), down 40%. TScan Therapeutics stock rose 276.1% that year.

Pay$100 in the stock at the end of FY21 → $130
Pay is from the Summary Compensation Table of each TScan Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. TScan TherapeuticsPublic company · 4 yr
    • Former President, Chief Executive Officer and Director2022 – Present · 4 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?